ZA200203181B - Positive modulators of nicotinic receptor agonists. - Google Patents

Positive modulators of nicotinic receptor agonists.

Info

Publication number
ZA200203181B
ZA200203181B ZA200203181A ZA200203181A ZA200203181B ZA 200203181 B ZA200203181 B ZA 200203181B ZA 200203181 A ZA200203181 A ZA 200203181A ZA 200203181 A ZA200203181 A ZA 200203181A ZA 200203181 B ZA200203181 B ZA 200203181B
Authority
ZA
South Africa
Prior art keywords
receptor agonists
nicotinic receptor
positive modulators
modulators
positive
Prior art date
Application number
ZA200203181A
Other languages
English (en)
Inventor
David Gurley
James Rosamond
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200203181B publication Critical patent/ZA200203181B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200203181A 1999-11-03 2002-04-22 Positive modulators of nicotinic receptor agonists. ZA200203181B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903998A SE9903998D0 (sv) 1999-11-03 1999-11-03 New compounds

Publications (1)

Publication Number Publication Date
ZA200203181B true ZA200203181B (en) 2003-07-22

Family

ID=20417608

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203181A ZA200203181B (en) 1999-11-03 2002-04-22 Positive modulators of nicotinic receptor agonists.

Country Status (16)

Country Link
US (2) US7064143B1 (https=)
EP (1) EP1230218A1 (https=)
JP (1) JP2003513073A (https=)
KR (1) KR20020063175A (https=)
CN (1) CN1216864C (https=)
AU (1) AU783602B2 (https=)
BR (1) BR0015193A (https=)
CA (1) CA2387741A1 (https=)
CO (1) CO5280079A1 (https=)
IL (1) IL149096A0 (https=)
MX (1) MXPA02004240A (https=)
NO (1) NO323077B1 (https=)
NZ (1) NZ518449A (https=)
SE (1) SE9903998D0 (https=)
WO (1) WO2001032622A1 (https=)
ZA (1) ZA200203181B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162825A1 (en) * 2001-11-09 2003-08-28 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7244745B2 (en) 2002-08-30 2007-07-17 Memory Pharmaceuticals Corp. Heterocyclic compounds, methods for the preparation thereof, and uses thereof
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
AU2004312530A1 (en) 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
DE602005023965D1 (de) 2004-03-08 2010-11-18 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
EP1735306A2 (en) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
WO2005118539A1 (en) 2004-06-01 2005-12-15 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
ATE424821T1 (de) 2004-12-02 2009-03-15 Prosidion Ltd Pyrrolopyridin-2-karbonsäureamide
FR2888847B1 (fr) 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
EP1960355A1 (en) 2005-11-30 2008-08-27 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles and aza-substituted indoles
DE602006009138D1 (de) 2005-11-30 2009-10-22 Hoffmann La Roche 3-amino-2-arylpropylazaindole und anwendungen davon
ATE517086T1 (de) 2005-11-30 2011-08-15 Hoffmann La Roche Verfahren zur synthese von 3-amino-1- arylpropylindolen
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
MX2009007395A (es) * 2007-01-09 2009-07-17 Bayer Schering Pharma Ag Marcacion radioactiva por fluoracion de aziridinas.
EP1944288A1 (en) * 2007-01-09 2008-07-16 Bayer Schering Pharma Aktiengesellschaft Radiolabelling via fluorination of aziridines
CN103977003A (zh) * 2007-04-02 2014-08-13 帕金森氏病研究院 用于降低治疗的副作用的方法和组合物
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
PE20170923A1 (es) 2010-05-17 2017-07-12 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
AR085509A1 (es) 2011-03-09 2013-10-09 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE758766A (fr) * 1969-11-17 1971-05-10 Ici Ltd Nouveaux derives de la morpholine et de la
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
IE913204A1 (en) 1990-09-13 1992-02-25 Beecham Group Plc Novel compounds
HUT69705A (en) 1991-11-25 1995-09-28 Pfizer Indole derivatives
WO1993018026A1 (en) 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
FR2722686B1 (fr) * 1994-07-22 1996-08-30 Oreal Set, procede, dispositif et composition de teinture des fibres keratiniques
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
SE9903997D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds

Also Published As

Publication number Publication date
AU783602B2 (en) 2005-11-10
CO5280079A1 (es) 2003-05-30
CN1387513A (zh) 2002-12-25
US20050245595A1 (en) 2005-11-03
NO20022105L (no) 2002-07-02
CA2387741A1 (en) 2001-05-10
BR0015193A (pt) 2002-06-18
NZ518449A (en) 2004-07-30
EP1230218A1 (en) 2002-08-14
AU1426301A (en) 2001-05-14
CN1216864C (zh) 2005-08-31
IL149096A0 (en) 2002-11-10
NO20022105D0 (no) 2002-05-02
JP2003513073A (ja) 2003-04-08
MXPA02004240A (es) 2002-10-17
US7402604B2 (en) 2008-07-22
NO323077B1 (no) 2006-12-27
SE9903998D0 (sv) 1999-11-03
WO2001032622A1 (en) 2001-05-10
US7064143B1 (en) 2006-06-20
KR20020063175A (ko) 2002-08-01

Similar Documents

Publication Publication Date Title
ZA200203181B (en) Positive modulators of nicotinic receptor agonists.
ZA200203171B (en) Positive modulators of nicotinic receptor agonists.
ZA200108846B (en) Glucocorticoid receptor modulators.
AU5203999A (en) Beta3-adrenergic receptor agonists
AU1293101A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
ZA200200298B (en) C-Pyrazole A2A receptor agonists.
ZA200203450B (en) beta2-adrenergic receptor agonists.
ZA991301B (en) Glutamate receptor modulators.
AU2056700A (en) 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
MXPA01007033A (es) Heterociclos funcionalizados como moduladores de receptores de quimiocinas.
AU5095000A (en) Receptor interacting protein rip3
GB9903767D0 (en) Receptor assay
AU2441801A (en) Urotensin-ii receptor antagonists
IL146151A0 (en) Human-g-protein receptor
AU2001226387A1 (en) Methods of identifying modulators of the fgf receptor
IL148266A0 (en) Apo-2 receptor antibodies
AU5861900A (en) Receptor agonists and antagonists
AU1745501A (en) Positive modulators of nicotinic receptor agonists
PL348504A1 (en) Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators
AU2574801A (en) Selective iGLUR5 receptor antagonists
MXPA01011286A (es) Derivados de ciclocarbamato como moduladores de receptor de progesterona.
ZA986189B (en) Substituted 2-(benzaryl)pyridines.
AU5572500A (en) Vegf receptor antagonists
ZA200107630B (en) Cyclocarbamate derivatives as progesterone receptor modulators.
ZA200107633B (en) Cyclothiocarbamate derivatives as progesterone receptor modulators.